CRISPR Therapeutics AG (CRSP) Stock Price, Quote & AI Analysis
Live CRSP stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for CRISPR Therapeutics AG.
TradeVae provides AI-driven analysis and real-time market intelligence for CRISPR Therapeutics AG (CRSP), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.
AI Analysis
Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.
Generating AI analysis...
CRISPR Therapeutics AG's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.
CRISPR Therapeutics AG Overview
Company information
Company Overview
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Company Details
Technical Indicators
Key technical analysis metrics and signals
Loading technical indicators...
Valuation Metrics
Key valuation ratios and comparisons
Loading valuation metrics...
CRISPR Therapeutics AG Earnings & Financial Statements
Earnings Calendar
Upcoming earnings dates and historical surprises
Loading earnings calendar...
Financial Statements
Income statements, balance sheets, and cash flow
Loading income statements...
Loading balance sheets...
Loading cash flow statements...